<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
NPS PHARMACEUTICALS, INC.
________________________________________________________________________________
(Name of Issuer)
Common Stock, $.001 par value
________________________________________________________________________________
(Title of Class of Securities)
62936P103
_______________________________________________________________
(CUSIP Number)
Steven M. Odre, Esq. with a copy to:
Senior Vice President, Gary Olsen, Esq.
General Counsel and Secretary Latham & Watkins
Amgen Inc. 633 West Fifth Street
One Amgen Center Drive Suite 4000
Thousand Oaks, CA 91320-1789 Los Angeles, California 90071-2007
(805) 447-1000 (213) 485-1234
________________________________________________________________________________
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
December 13, 2000
_______________________________________________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of (S)(S)240.13d-1(e), 240.13d-1(f) or 240.13d-7(g), check the
following box [_].
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See (S) 240.13d-7(b) for
other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
SCHEDULE 13D
----------------------- ---------------------
CUSIP NO. 62936P103 PAGE 2 OF 10 PAGES
----------------------- ---------------------
------------------------------------------------------------------------------
NAME OF REPORTING PERSON
1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
AMGEN INC.
------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
2 (a) [_]
(b) [_]
------------------------------------------------------------------------------
SEC USE ONLY
3
------------------------------------------------------------------------------
SOURCE OF FUNDS (SEE INSTRUCTIONS)
4
N/A
------------------------------------------------------------------------------
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e) [_]
5
------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
DELAWARE
------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 1,000,000 shares
SHARES -----------------------------------------------------------
SHARED VOTING POWER
BENEFICIALLY 8
N/A
OWNED BY
-----------------------------------------------------------
EACH SOLE DISPOSITIVE POWER
9
REPORTING 1,000,000 shares
PERSON -----------------------------------------------------------
SHARED DISPOSITIVE POWER
WITH 10
N/A
------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
1,000,000 shares
------------------------------------------------------------------------------
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
12 (SEE INSTRUCTIONS)
[_] N/A
------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
3.99%
------------------------------------------------------------------------------
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
14
CO
------------------------------------------------------------------------------
<PAGE>
This Amendment No. 1 to Schedule 13D is being filed by Amgen Inc., a
Delaware corporation (the "Reporting Person"), to amend the Schedule 13D filed
on December 22, 1998, relating to shares of Common Stock of $0.001 par value
("Common Stock"), of NPS Pharmaceuticals, Inc., a Delaware corporation (the
"Issuer"). The Reporting Person has fallen below the five percent threshold of
ownership of the Issuer's Common Stock for reporting under Section 13(d) of the
Securities Exchange Act of 1934, as amended. Unless otherwise indicated, all
capitalized terms used herein but not defined herein shall have the meaning
assigned to them in the Schedule 13D.
3
<PAGE>
Item 5. Interest in Securities of the Issuer
------
(a) As of the date of this Schedule 13D, Amgen beneficially owns 1,000,000
shares of the Issuer's Common Stock (the "Shares") which is approximately
3.99% of the outstanding shares of the Issuer's Common Stock as identified
in the Issuer's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2000.
(b) Amgen has the sole power to vote or to direct the vote and sole power to
dispose or to direct the disposition of the Shares.
(c) There were no other transactions in the Common Stock of the Issuer that
were effected during the past sixty days by Amgen.
(d) To the best knowledge of Amgen, no person other than Amgen has the right to
receive or the power to direct the receipt of dividends from, or the
proceeds from the sale of the Shares.
(e) NA
4
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: December 13, 2000
AMGEN INC.
BY: /s/ Kathryn E. Falberg
----------------------------------
Kathryn E. Falberg
Senior Vice President, Finance
and Corporate Development,
and Chief Financial Officer
